Tactile Systems Technology Inc. (TCMD) Insider Trading

Last 12 months

Insiders sold $2.02M and bought nothing on the open market.

7% of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Aug 2022.

Net open-market

−$2.02M

0 buys · 9 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 3

executives and directors

Last open-market buy

Aug 2022

Aug 4, 2022

Get an email when TCMD's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 10	Sheri Louise Dodd Chief Executive Officer	SoldNo plan	10,978	$29.44	$323k	4.5%	Form 4
May 11	Elaine M. Birkemeyer CHIEF FINANCIAL OFFICER	SoldNo plan	4,631	$24.49	$113k	3.4%	Form 4
Feb 24	Elaine M. Birkemeyer CHIEF FINANCIAL OFFICER	SoldNo plan	7,701	$28.94	$223k	5.4%	Form 4
Feb 24	Kristie Burns Sr. VP Mktg & Clinical Affairs	SoldNo plan	6,246	$28.94	$181k	7.0%	Form 4
Feb 24	Sheri Louise Dodd Chief Executive Officer	SoldNo plan	10,993	$28.94	$318k	4.3%	Form 4
Feb 23	Elaine M. Birkemeyer CHIEF FINANCIAL OFFICER	SoldNo plan 2 parts	5,518	$28.29 average	$156k	3.7%	Form 4
Feb 23	Kristie Burns Sr. VP Mktg & Clinical Affairs	SoldNo plan 2 parts	4,439	$28.29 average	$126k	4.8%	Form 4
Feb 23	Sheri Louise Dodd Chief Executive Officer	SoldNo plan 2 parts	15,240	$28.29 average	$431k	5.6%	Form 4
Jan 2	Kristie Burns Sr. VP Mktg & Clinical Affairs	Sold10b5-1 plan	5,139	$28.85	$148k	6.6%	Form 4
Aug 8, 2025	Sheri Louise Dodd Chief Executive Officer	SoldNo plan	7,762	$12.36	$96k	4.3%	Form 4
May 12, 2025	Elaine M. Birkemeyer Chief Financial Officer	Sold10b5-1 plan	2,921	$9.94	$29k	2.9%	Form 4
May 8, 2025	Sheri Louise Dodd Chief Executive Officer	SoldNo plan	3,149	$9.83	$31k	1.7%	Form 4
May 8, 2025	William W Burke Director	Sold10b5-1 plan	3,300	$9.67	$32k	6.4%	Form 4
Feb 25, 2025	Elaine M. Birkemeyer Chief Financial Officer	Sold10b5-1 plan	2,066	$14.51	$30k	2.0%	Form 4
Feb 25, 2025	Kristie Burns Sr. VP Mktg & Clinical Affairs	SoldNo plan	6,468	$14.40	$93k	7.7%	Form 4
Feb 25, 2025	Daniel L. Reuvers Director	Sold10b5-1 plan	28,338	$14.18	$402k	12%	Form 4
Feb 24, 2025	Daniel L. Reuvers Director	Sold10b5-1 plan	10,938	$14.55	$159k	4.3%	Form 4
Feb 24, 2025	Kristie Burns Sr. VP Mktg & Clinical Affairs	SoldNo plan	4,830	$14.65	$71k	5.4%	Form 4
Feb 24, 2025	Elaine M. Birkemeyer Chief Financial Officer	Sold10b5-1 plan	3,778	$14.70	$56k	3.5%	Form 4

Aug 10No plan
Sheri Louise Dodd
Chief Executive Officer · sold 10,978 at $29.44
$323k
4.5% of stake
May 11No plan
Elaine M. Birkemeyer
CHIEF FINANCIAL OFFICER · sold 4,631 at $24.49
$113k
3.4% of stake
Feb 24No plan
Elaine M. Birkemeyer
CHIEF FINANCIAL OFFICER · sold 7,701 at $28.94
$223k
5.4% of stake
Feb 24No plan
Kristie Burns
Sr. VP Mktg & Clinical Affairs · sold 6,246 at $28.94
$181k
7.0% of stake
Feb 24No plan
Sheri Louise Dodd
Chief Executive Officer · sold 10,993 at $28.94
$318k
4.3% of stake
Feb 23No plan
Elaine M. Birkemeyer
CHIEF FINANCIAL OFFICER · sold 5,518 at avg $28.29
$156k
3.7% of stake
Feb 23No plan
Kristie Burns
Sr. VP Mktg & Clinical Affairs · sold 4,439 at avg $28.29
$126k
4.8% of stake
Feb 23No plan
Sheri Louise Dodd
Chief Executive Officer · sold 15,240 at avg $28.29
$431k
5.6% of stake
Jan 210b5-1 plan
Kristie Burns
Sr. VP Mktg & Clinical Affairs · sold 5,139 at $28.85
$148k
6.6% of stake
Aug 8, 2025No plan
Sheri Louise Dodd
Chief Executive Officer · sold 7,762 at $12.36
$96k
4.3% of stake
May 12, 202510b5-1 plan
Elaine M. Birkemeyer
Chief Financial Officer · sold 2,921 at $9.94
$29k
2.9% of stake
May 8, 2025No plan
Sheri Louise Dodd
Chief Executive Officer · sold 3,149 at $9.83
$31k
1.7% of stake
May 8, 202510b5-1 plan
William W Burke
Director · sold 3,300 at $9.67
$32k
6.4% of stake
Feb 25, 202510b5-1 plan
Elaine M. Birkemeyer
Chief Financial Officer · sold 2,066 at $14.51
$30k
2.0% of stake
Feb 25, 2025No plan
Kristie Burns
Sr. VP Mktg & Clinical Affairs · sold 6,468 at $14.40
$93k
7.7% of stake
Feb 25, 202510b5-1 plan
Daniel L. Reuvers
Director · sold 28,338 at $14.18
$402k
12% of stake
Feb 24, 202510b5-1 plan
Daniel L. Reuvers
Director · sold 10,938 at $14.55
$159k
4.3% of stake
Feb 24, 2025No plan
Kristie Burns
Sr. VP Mktg & Clinical Affairs · sold 4,830 at $14.65
$71k
5.4% of stake
Feb 24, 202510b5-1 plan
Elaine M. Birkemeyer
Chief Financial Officer · sold 3,778 at $14.70
$56k
3.5% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch TCMD, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Surgical & Medical Instruments & Apparatus

MDXGMiMedx Group, Inc.

PRCTProcept BioRobotics Corporation

ANGOAngiodynamics Inc.

SKINSkinHealth Systems Inc.

ARAYAccuray Incorporated

LMATLemaitre Vascular Inc.

KIDSOrthoPediatrics Corp.

AORTArtivion Inc.

Spot a number that looks wrong? Check it in TCMD's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing TCMD

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.